Genetic approaches for changing the heart and dissecting complex syndromes

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 2, 2008, Pages 148-155

  Moga, Michael Alice ^a   Nakamura, Tomoki ^a   Robbins, Jeffrey ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cardiac function; Gene targeting; Genetics; Mouse; Transgenesis

Indexed keywords

GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC MANIPULATION; GENOME; HEART DISEASE; HEART FUNCTION; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN CONTENT; REVIEW; TRANSGENICS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE TARGETING; GENE TRANSFER TECHNIQUES; HEART; HEART DISEASES; HUMANS; MODELS, CARDIOVASCULAR; MUTAGENESIS, INSERTIONAL; SYNDROME;

ANIMALIA; MAMMALIA;

EID: 49049102691     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.06.002     Document Type: Review

References (104)

1. Robbins J. Gene targeting. The precise manipulation of the mammalian genome. Circ Res 73 (1993) 3-9
2. Mortensen R.M. Double knockouts. Production of mutant cell lines in cardiovascular research. Hypertension 22 (1993) 646-651
3. Nabel E.G., Plautz G., and Nabel G.J. Gene transfer into vascular cells. J Am Coll Cardiol 17 (1991) 189B-194B
4. Freimuth P. Protein overexpression in mammalian cell lines. Genet Eng (N Y) 28 (2007) 95-104
5. Heine H.L., Leong H.S., Rossi F.M., McManus B.M., and Podor T.J. Strategies of conditional gene expression in myocardium: an overview. Methods Mol Med 112 (2005) 109-154
6. Albanese C., Hulit J., Sakamaki T., and Pestell R.G. Recent advances in inducible expression in transgenic mice. Semin Cell Dev Biol 13 (2002) 129-141
7. Brinster R.L., Chen H.Y., Trumbauer M., Senear A.W., Warren R., and Palmiter R.D. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27 (1981) 223-231
8. Gordon K., and Ruddle F.H. Gene transfer into mouse embryos. Dev Biol (N Y 1985) 4 (1986) 1-36
9. Palmiter R.D., and Brinster R.L. Transgenic mice. Cell 41 (1985) 343-345
10. Supp D.M., Brueckner M., Kuehn M.R., Witte D.P., Lowe L.A., McGrath J., et al. Targeted deletion of the ATP binding domain of left-right dynein confirms its role in specifying development of left-right asymmetries. Development 126 (1999) 5495-5504
11. Supp D.M., Witte D.P., Potter S.S., and Brueckner M. Mutation of an axonemal dynein affects left-right asymmetry in inversus viscerum mice. Nature 389 (1997) 963-966
12. Gulick J., Hewett T.E., Klevitsky R., Buck S.H., Moss R.L., and Robbins J. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart. Circ Res 80 (1997) 655-664
13. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92 (2003) 609-616
14. James J., Osinska H., Hewett T.E., Kimball T., Klevitsky R., Witt S., et al. Transgenic over-expression of a motor protein at high levels results in severe cardiac pathology. Transgenic Res 8 (1999) 9-22
15. Chien K.R. To Cre or not to Cre: the next generation of mouse models of human cardiac diseases. Circ Res 88 (2001) 546-549
16. Huang W.Y., Aramburu J., Douglas P.S., and Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med 6 (2000) 482-483
17. Babinet C., Morello D., and Renard J.P. Transgenic mice. Genome 31 (1989) 938-949
18. Field L.J. Transgenic mice in cardiovascular research. Annu Rev Physiol 55 (1993) 97-114
19. Hunter J.J., Tanaka N., Rockman H.A., Ross Jr. J., and Chien K.R. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 270 (1995) 23173-23178
20. Hunter J.J., Zhu H., Lee K.J., Kubalak S., and Chien K.R. Targeting gene expression to specific cardiovascular cell types in transgenic mice. Hypertension 22 (1993) 608-617
21. Knotts S., Rindt H., Neumann J., and Robbins J. In vivo regulation of the mouse beta myosin heavy chain gene. J Biol Chem 269 (1994) 31275-31282
22. Robbins J., Palermo J., and Rindt H. In vivo definition of a cardiac specific promoter and its potential utility in remodeling the heart. Ann N Y Acad Sci 752 (1995) 492-505
23. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., and Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266 (1991) 24613-24620
24. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol 62 (2000) 261-287
25. Buttrick P.M., Kaplan M.L., Kitsis R.N., and Leinwand L.A. Distinct behavior of cardiac myosin heavy chain gene constructs in vivo. Discordance with in vitro results. Circ Res 72 (1993) 1211-1217
26. Buttrick P.M., Kass A., Kitsis R.N., Kaplan M.L., and Leinwand L.A. Behavior of genes directly injected into the rat heart in vivo. Circ Res 70 (1992) 193-198
27. Knotts S., Rindt H., and Robbins J. Position independent expression and developmental regulation is directed by the beta myosin heavy chain gene's 5′ upstream region in transgenic mice. Nucleic Acids Res 23 (1995) 3301-3309
28. Soonpaa M.H., and Field L.J. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 83 (1998) 15-26
29. Chen J., Kubalak S.W., and Chien K.R. Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development 125 (1998) 1943-1949
30. Mochly-Rosen D., Wu G., Hahn H., Osinska H., Liron T., Lorenz J.N., et al. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res 86 (2000) 1173-1179
31. De Windt L.J., Lim H.W., Bueno O.F., Liang Q., Delling U., Braz J.C., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 98 (2001) 3322-3327
32. Syed F., Odley A., Hahn H.S., Brunskill E.W., Lynch R.A., Marreez Y., et al. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 95 (2004) 1200-1206
33. Dorn II G.W., Robbins J., Ball N., and Walsh R.A. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol 267 (1994) H400-H405
34. Izumo S., Nadal-Ginard B., and Mahdavi V. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific manner. Science 231 (1986) 597-600
35. Bujard H. Controlling genes with tetracyclines. J Gene Med 1 (1999) 372-374
36. Gossen M., Bonin A.L., Freundlieb S., and Bujard H. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol 5 (1994) 516-520
37. Mansuy I.M., Winder D.G., Moallem T.M., Osman M., Mayford M., Hawkins R.D., et al. Inducible and reversible gene expression with the rtTA system for the study of memory. Neuron 21 (1998) 257-265
38. Freundlieb S., Baron U., Bonin A.L., Gossen M., and Bujard H. Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. Methods Enzymol 283 (1997) 159-173
39. Freundlieb S., Schirra-Muller C., and Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1 (1999) 4-12
40. Russell L.K., Mansfield C.M., Lehman J.J., Kovacs A., Courtois M., Saffitz J.E., et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94 (2004) 525-533
41. Capecchi M.R. Altering the genome by homologous recombination. Science 244 (1989) 1288-1292
42. Bronson S.K., Plaehn E.G., Kluckman K.D., Hagaman J.R., Maeda N., and Smithies O. Single-copy transgenic mice with chosen-site integration. Proc Natl Acad Sci U S A 93 (1996) 9067-9072
43. Askew G.R., Doetschman T., and Lingrel J.B. Site-directed point mutations in embryonic stem cells: a gene-targeting tag-and-exchange strategy. Mol Cell Biol 13 (1993) 4115-4124
44. Hasty P., Ramirez-Solis R., Krumlauf R., and Bradley A. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature 350 (1991) 243-246
45. Lewis J., Yang B., Detloff P., and Smithies O. Gene modification via "plug and socket" gene targeting. J Clin Invest 97 (1996) 3-5
46. Valancius V., and Smithies O. Testing an "in-out" targeting procedure for making subtle genomic modifications in mouse embryonic stem cells. Mol Cell Biol 11 (1991) 1402-1408
47. Marth J.D. Recent advances in gene mutagenesis by site-directed recombination. J Clin Invest 97 (1996) 1999-2002
48. Rajewsky K., Gu H., Kuhn R., Betz U.A., Muller W., Roes J., et al. Conditional gene targeting. J Clin Invest 98 (1996) 600-603
49. Yoshioka J., Imahashi K., Gabel S.A., Chutkow W.A., Burds A.A., Gannon J., et al. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101 (2007) 1328-1338
50. Holtwick R., van Eickels M., Skryabin B.V., Baba H.A., Bubikat A., Begrow F., et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 (2003) 1399-1407
51. Agah R., Frenkel P.A., French B.A., Michael L.H., Overbeek P.A., and Schneider M.D. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest 100 (1997) 169-179
52. Sohal D.S., Nghiem M., Crackower M.A., Witt S.A., Kimball T.R., Tymitz K.M., et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89 (2001) 20-25
53. Williams R.W., Flaherty L., and Threadgill D.W. The math of making mutant mice. Genes Brain Behav 2 (2003) 191-200
54. Braun T., and Arnold H.H. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. Embo J 14 (1995) 1176-1186
55. Patapoutian A., Yoon J.K., Miner J.H., Wang S., Stark K., and Wold B. Disruption of the mouse MRF4 gene identifies multiple waves of myogenesis in the myotome. Development 121 (1995) 3347-3358
56. Zhang W., Behringer R.R., and Olson E.N. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev 9 (1995) 1388-1399
57. Noonan J.A. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116 (1968) 373-380
58. Mendez H.M., and Opitz J.M. Noonan syndrome: a review. Am J Med Genet 21 (1985) 493-506
59. Shah N., Rodriguez M., Louis D.S., Lindley K., and Milla P.J. Feeding difficulties and foregut dysmotility in Noonan's syndrome. Arch Dis Child 81 (1999) 28-31
60. Chan R.J., and Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109 (2007) 862-867
61. Neel B.G., Gu H., and Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28 (2003) 284-293
62. Keilhack H., David F.S., McGregor M., Cantley L.C., and Neel B.G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280 (2005) 30984-30993
63. Bard-Chapeau E.A., Yuan J., Droin N., Long S., Zhang E.E., Nguyen T.V., et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol Cell Biol 26 (2006) 4664-4674
64. Zhang E.E., Chapeau E., Hagihara K., and Feng G.S. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc Natl Acad Sci U S A 101 (2004) 16064-16069
65. Ke Y., Lesperance J., Zhang E.E., Bard-Chapeau E.A., Oshima R.G., Muller W.J., et al. Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J Biol Chem 281 (2006) 34374-34380
66. Mohi M.G., and Neel B.G. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17 (2007) 23-30
67. Saxton T.M., Ciruna B.G., Holmyard D., Kulkarni S., Harpal K., Rossant J., et al. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet 24 (2000) 420-423
68. Edouard T., Montagner A., Dance M., Conte F., Yart A., Parfait B., et al. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?. Cell Mol Life Sci 64 (2007) 1585-1590
69. Tartaglia M., Pennacchio L.A., Zhao C., Yadav K.K., Fodale V., Sarkozy A., et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39 (2007) 75-79
70. Schubbert S., Zenker M., Rowe S.L., Boll S., Klein C., Bollag G., et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 38 (2006) 331-336
71. Roberts A.E., Araki T., Swanson K.D., Montgomery K.T., Schiripo T.A., Joshi V.A., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39 (2007) 70-74
72. Tartaglia M., and Gelb B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6 (2005) 45-68
73. Hanna N., Montagner A., Lee W.H., Miteva M., Vidal M., Vidaud M., et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 580 (2006) 2477-2482
74. Kontaridis M.I., Swanson K.D., David F.S., Barford D., and Neel B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281 (2006) 6785-6792
75. Tartaglia M., Martinelli S., Stella L., Bocchinfuso G., Flex E., Cordeddu V., et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78 (2006) 279-290
76. Ohtani T., Ishihara K., Atsumi T., Nishida K., Kaneko Y., Miyata T., et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12 (2000) 95-105
77. Hagiwara Y., Miyoshi S., Fukuda K., Nishiyama N., Ikegami Y., Tanimoto K., et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 43 (2007) 710-716
78. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10 (2004) 849-857
79. Nakamura T., Colbert M., Krenz M., Molkentin J.D., Hahn H.S., Dorn II G.W., et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117 (2007) 2123-2132
80. Krenz M., Yutzey K.E., and Robbins J. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ Res 97 (2005) 813-820
81. Corson L.B., Yamanaka Y., Lai K.M., and Rossant J. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130 (2003) 4527-4537
82. Saba-El-Leil M.K., Vella F.D., Vernay B., Voisin L., Chen L., Labrecque N., et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4 (2003) 964-968
83. Pages G., Guerin S., Grall D., Bonino F., Smith A., Anjuere F., et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286 (1999) 1374-1377
84. Morales A.V., Barbas J.A., and Nieto M.A. How to become neural crest: from segregation to delamination. Semin Cell Dev Biol 16 (2005) 655-662
85. Crane J.F., and Trainor P.A. Neural crest stem and progenitor cells. Annu Rev Cell Dev Biol 22 (2006) 267-286
86. Stoller J.Z., and Epstein J.A. Cardiac neural crest. Semin Cell Dev Biol 16 (2005) 704-715
87. Maschhoff K.L., and Baldwin H.S. Molecular determinants of neural crest migration. Am J Med Genet 97 (2000) 280-288
88. Li J., Molkentin J.D., and Colbert M.C. Retinoic acid inhibits cardiac neural crest migration by blocking c-Jun N-terminal kinase activation. Dev Biol 232 (2001) 351-361
89. Snider P., Olaopa M., Firulli A.B., and Conway S.J. Cardiovascular development and the colonizing cardiac neural crest lineage. Scientific World J 7 (2007) 1090-1113
90. Hutson M.R., and Kirby M.L. Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations. Semin Cell Dev Biol 18 (2007) 101-110
91. Hutson M.R., and Kirby M.L. Neural crest and cardiovascular development: a 20-year perspective. Birth Defects Res C Embryo Today 69 (2003) 2-13
92. Brown C.B., and Baldwin H.S. Neural crest contribution to the cardiovascular system. Adv Exp Med Biol 589 (2006) 134-154
93. Lee M., Brennan A., Blanchard A., Zoidl G., Dong Z., Tabernero A., et al. P0 is constitutively expressed in the rat neural crest and embryonic nerves and is negatively and positively regulated by axons to generate non-myelin-forming and myelin-forming Schwann cells, respectively. Mol Cell Neurosci 8 (1997) 336-350
94. Jiang X., Rowitch D.H., Soriano P., McMahon A.P., and Sucov H.M. Fate of the mammalian cardiac neural crest. Development 127 (2000) 1607-1616
95. Brown C.B., Feiner L., Lu M.M., Li J., Ma X., Webber A.L., et al. PlexinA2 and semaphorin signaling during cardiac neural crest development. Development 128 (2001) 3071-3080
96. Nakamura T., Colbert M.C., and Robbins J. Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system. Circ Res 98 (2006) 1547-1554
97. Jiang X., Iseki S., Maxson R.E., Sucov H.M., and Morriss-Kay G.M. Tissue origins and interactions in the mammalian skull vault. Dev Biol 241 (2002) 106-116
98. Chai Y., Jiang X., Ito Y., Bringas Jr. P., Han J., Rowitch D.H., et al. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 127 (2000) 1671-1679
99. Mello C.C., and Conte Jr. D. Revealing the world of RNA interference. Nature 431 (2004) 338-342
100. Luther H.P. Role of endogenous antisense RNA in cardiac gene regulation. J Mol Med 83 (2005) 26-32
101. Fire A.Z. Gene silencing by double-stranded RNA. Cell Death Differ 14 (2007) 1998-2012
102. Kasahara H., and Aoki H. Gene silencing using adenoviral RNAi vector in vascular smooth muscle cells and cardiomyocytes. Methods Mol Med 112 (2005) 155-172
103. Zhao Y., Ransom J.F., Li A., Vedantham V., von Drehle M., Muth A.N., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129 (2007) 303-317
104. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103 (2006) 18255-18260